Post-approval studies (Phase 4)Ended earlyNCT01467492
What this trial is testing
Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C
Who this might be right for
Hepatitis C
Vertex Pharmaceuticals Incorporated 121